Amitriptyline is efficacious in ameliorating muscle inflammation and depressive symptoms in the mdx mouse model of Duchenne muscular dystrophy

Experimental Physiology

Volumn 99, Issue 10, 2014, Pages 1370-1386

  Manning, Jennifer ^a   Kulbida, Rebecca ^a   Rai, Prerana ^b   Jensen, Lindsay ^b   Bouma, Judith ^b   Singh, Sanjay P ^b   O'Malley, D ^a   Yilmazer Hanke, Deniz ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; AMITRIPTYLINE; BRAIN MONOAMINE; DOPAMINE; HOMOVANILLIC ACID; INTERLEUKIN 6; MESSENGER RNA; NORADRENALIN; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA; TRICYCLIC ANTIDEPRESSANT AGENT;

AMYGDALOID NUCLEUS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DRUG EFFICACY; DRUG MUSCLE LEVEL; DUCHENNE MUSCULAR DYSTROPHY; HIPPOCAMPUS; HYPOTHALAMUS; IMMUNOCOMPETENT CELL; LEARNING; MALE; MESENCEPHALON; MOOD; MOUSE; MYOSITIS; NONHUMAN; OPEN FIELD TEST; PREFRONTAL CORTEX; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TAIL SUSPENSION TEST; TRANQUILIZING ACTIVITY; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE; ANIMAL; DISEASE MODEL; DRUG EFFECTS; INFLAMMATION; MUSCULAR DYSTROPHY, DUCHENNE; PATHOLOGY; PSYCHOLOGY; SKELETAL MUSCLE;

AMITRIPTYLINE; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BEHAVIOR, ANIMAL; DEPRESSION; DISEASE MODELS, ANIMAL; INFLAMMATION; LEARNING; MICE; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE;

EID: 84908478691     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2014.079475     Document Type: Article

References (78)

1. Abdel-Salam OM, Nofal SM & El-Shenawy SM (2003). Evaluation of the anti-inflammatory and anti-nociceptive effects of different antidepressants in the rat. Pharmacol Res 48, 157-165.
2. Achar E, Maciel TT, Collares CF, Teixeira VP & Schor N (2009). Amitriptyline attenuates interstitial inflammation and ameliorates the progression of renal fibrosis. Kidney Int 75, 596-604.
3. Amado-Boccara I, Gougoulis N, Poirier Littre MF, Galinowski A & Loo H (1995). Effects of antidepressants on cognitive functions: a review. Neurosci Biobehav Rev 19, 479-493.
4. Anderson JE, Ovalle WK & Bressler BH (1987). Electron microscopic and autoradiographic characterization of hindlimb muscle regeneration in the mdx mouse. Anat Rec 219, 243-257.
5. Anderson JL, Head SI, Rae C & Morley JW (2002). Brain function in Duchenne muscular dystrophy. Brain 125, 4-13.
6. Barbui C & Hotopf M (2001). Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials. Br J Psychiatry 178, 129-144.
7. Beck JA, Lloyd S, Hafezparast M, Lennon-Pierce M, Eppig JT, Festing MF & Fisher EM (2000). Genealogies of mouse inbred strains. Nat Genet 24, 23-25.
8. Bremner JD, Vythilingam M, Vermetten E, Nazeer A, Adil J, Khan S, Staib LH & Charney DS (2002). Reduced volume of orbitofrontal cortex in major depression. Biol Psychiatry 51, 273-279.
9. Briguet A, Courdier-Fruh I, Foster M, Meier T & Magyar JP (2004). Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse. Neuromuscul Disord 14, 675-682.
10. Broquet KE (1999). Status of treatment of depression. South Med J 92, 846-856.
11. Caldarone BJ, Karthigeyan K, Harrist A, Hunsberger JG, Wittmack E, King SL, Jatlow P & Picciotto MR (2003). Sex differences in response to oral amitriptyline in three animal models of depression in C57BL/6J mice. Psychopharmacology (Berl) 170, 94-101.
12. Carre-Pierrat M, Lafoux A, Tanniou G, Chambonnier L, Divet A, Fougerousse F, Huchet-Cadiou C & Ségalat L (2011). Pre-clinical study of 21 approved drugs in the mdx mouse. Neuromuscul Disord 21, 313-327.
13. Carre-Pierrat M, Mariol MC, Chambonnier L, Laugraud A, Heskia F, Giacomotto J & Ségalat L (2006). Blocking of striated muscle degeneration by serotonin in C. elegans. J Muscle Res Cell Motil 27, 253-258.
14. Chamberlain JS, Farwell NJ, Chamberlain JR, Cox GA & Caskey CT (1991). PCR analysis of dystrophin gene mutation and expression. J Cell Biochem 46, 255-259.
15. Damsa C, Bumb A, Bianchi-Demicheli F, Vidailhet P, Sterck R, Andreoli A & Beyenburg S (2004). 'Dopamine-dependent' side effects of selective serotonin reuptake inhibitors: a clinical review. J Clin Psychiatry 65, 1064-1068.
16. Delgado PL (2000). Depression: the case for a monoamine deficiency. J Clin Psychiatry 61 Suppl 6, 7-11.
17. Fitzpatrick C, Barry C & Garvey C (1986). Psychiatric disorder among boys with Duchenne muscular dystrophy. Dev Med Child Neurol 28, 589-595.
18. Goldenberg D, Mayskiy M, Mossey C, Ruthazer R & Schmid C (1996). A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 39, 1852-1859.
19. Górka Z & Maj J (1986). Effects of repeated treatment with antidepressant drugs on the 24 h behaviour in the light-dark synchronized mice. Pol J Pharmacol Pharm 38, 493-499.
20. Grounds MD (2008). Two-tiered hypotheses for Duchenne muscular dystrophy. Cell Mol Life Sci 65, 1621-1625.
21. Guaiana G, Barbui C & Hotopf M (2007). Amitriptyline for depression. Cochrane Database Syst Rev (3), CD004186.
22. Gubern C, Hurtado O, Rodríguez R, Morales JR, Romera VG, Moro MA, Lizasoain I, Serena J & Mallolas J (2009). Validation of housekeeping genes for quantitative real-time PCR in in-vivo and in-vitro models of cerebral ischaemia. BMC Mol Biol 10, 57.
23. Hajhashemi V, Sadeghi H, Minaiyan M, Movahedian A & Talebi A (2010). The role of central mechanisms in the anti-inflammatory effect of amitriptyline on carrageenan-induced paw edema in rats. Clinics (Sao Paulo) 65, 1183-1187.
24. Hall CS (1936). Emotional behaviour in the rat: III. The relationship between emotionality and ambulatory activity. J Comp Psychol 22, 345-352.
25. Inglis J, Jones RP & Sloane RB (1963). A psychiatric and psychological study of amitriptyline (Elavil) as an antidepressant. Can Med Assoc J 88, 797-802.
26. Judge DP, Kass DA, Thompson WR & Wagner KR (2011). Pathophysiology and therapy of cardiac dysfunction in Duchenne muscular dystrophy. Am J Cardiovasc Drugs 11, 287-294.
27. Kalkman JS, Schillings ML, Zwarts MJ, van Engelen BG & Bleijenberg G (2007a). Psychiatric disorders appear equally in patients with myotonic dystrophy, facioscapulohumeral dystrophy, and hereditary motor and sensory neuropathy type I. Acta Neurol Scand 115, 265-270.
28. Kalkman JS, Schillings ML, Zwarts MJ, van Engelen BG & Bleijenberg G (2007b). The development of a model of fatigue in neuromuscular disorders: a longitudinal study. J Psychosom Res 62, 571-579.
29. Kostek MC, Nagaraju K, Pistilli E, Sali A, Lai SH, Gordon B & Chen YW (2012). IL-6 signalling blockade increases inflammation but does not affect muscle function in the mdx mouse. BMC Musculoskelet Disord 13, 106.
30. Kubera M, Maes M, Kenis G, Kim YK & Lasoń W (2005). Effects of serotonin and serotonergic agonists and antagonists on the production of tumor necrosis factor α and interleukin-6. Psychiatry Res 134, 251-258.
31. Kurina LM, Goldacre MJ, Yeates D & Gill LE (2001). Depression and anxiety in people with inflammatory bowel disease. J Epidemiol Community Health 55, 716-720.
32. Leonard B & Maes M (2012). Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 36, 764-785.
33. Lidov HG (1996). Dystrophin in the nervous system. Brain Pathol 6, 63-77.
34. Malemud CJ & Miller AH (2008). Pro-inflammatory cytokine-induced SAPK/MAPK and JAK/STAT in rheumatoid arthritis and the new anti-depression drugs. Expert Opin Ther Targets 12, 171-183.
35. Manzur AY, Kuntzer T, Pike M & Swan A (2008). Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev (1), CD003725.
36. Meneses A & Hong E (1997). A pharmacological analysis of serotonergic receptors: effects of their activation of blockade in learning. Prog Neuropsychopharmacol Biol Psychiatry 21, 273-296.
37. Minoura Y, Di Diego JM, Barajas-Martínez H, Zygmunt AC, Hu D, Sicouri S & Antzelevitch C (2012). Ionic and cellular mechanisms underlying the development of acquired Brugada syndrome in patients treated with antidepressants. J Cardiovasc Electrophysiol 23, 423-432.
38. Muntoni F, Mateddu A & Serra G (1991). Passive avoidance behaviour deficit in the mdx mouse. Neuromuscul Disord 1, 121-123.
39. Naughton M, Mulrooney JB & Leonard BE (2000). A review of the role of serotonin receptors in psychiatric disorders. Hum Psychopharmacol 15, 397-415.
40. O'Malley D, Julio-Pieper M, Gibney SM, Dinan TG & Cryan JF (2010). Distinct alterations in colonic morphology and physiology in two rat models of enhanced stress-induced anxiety and depression-like behaviour. Stress 13, 114-122.
41. Orsetti M, Colella L, Dellarole A, Canonico PL & Ghi P (2007). Modification of spatial recognition memory and object discrimination after chronic administration of haloperidol, amitriptyline, sodium valproate or olanzapine in normal and anhedonic rats. Int J Neuropsychopharmacol 10, 345-357.
42. 2A receptor antagonist exhibits antidepressant-like effects in a battery of rodent behavioural assays: approaching early-onset antidepressants. Pharmacol Biochem Behav 94, 363-373.
43. Pedersen BK & Febbraio MA (2008). Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 88, 1379-1406.
44. Petrof BJ, Shrager JB, Stedman HH, Kelly AM & Sweeney HL (1993). Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A 90, 3710-3714.
45. Porter JD, Khanna S, Kaminski HJ, Rao JS, Merriam AP, Richmonds CR, Leahy P, Li J, Guo W & Andrade FH (2002). A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet 11, 263-272.
46. Pousset F, Fournier J, Legoux P, Keane P, Shire D & Soubrie P (1996). Effect of serotonin on cytokine mRNA expression in rat hippocampal astrocytes. Brain Res Mol Brain Res 38, 54-62.
47. Ritchie PK, Ashby M, Knight HH & Judd AM (1996a). Dopamine increases interleukin 6 release and inhibits tumor necrosis factor release from rat adrenal zona glomerulosa cells in vitro. Eur J Endocrinol 134, 610-616.
48. Ritchie PK, Knight HH, Ashby M & Judd AM (1996b). Serotonin increases interleukin-6 release and decreases tumor necrosis factor release from rat adrenal zona glomerulosa cells in vitro. Endocrine 5, 291-297.
49. Roccella M, Pace R & De Gregorio MT (2003). Psychopathological assessment in children affected by Duchenne de Boulogne muscular dystrophy. Minerva Pediatr 55, 267-273, 273-266.
50. Rosen JB & Schulkin J (1998). From normal fear to pathological anxiety. Psychol Rev 105, 325-350.
51. Rosenblat JD, Cha DS, Mansur RB & McIntyre RS (2014). Inflamed moods: A review of the interactions between inflammation and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry 53C, 23-34.
52. Rubinsztein JS, Rubinsztein DC, Goodburn S & Holland AJ (1998). Apathy and hypersomnia are common features of myotonic dystrophy. J Neurol Neurosurg Psychiatry 64, 510-515.
53. Sandi C, Cordero MI, Ugolini A, Varea E, Caberlotto L & Large CH (2008). Chronic stress-induced alterations in amygdala responsiveness and behaviour - modulation by trait anxiety and corticotropin-releasing factor systems. Eur J Neurosci 28, 1836-1848.
54. Sapolsky RM (2001). Depression, antidepressants, and the shrinking hippocampus. Proc Natl Acad Sci U S A 98, 12320-12322.
55. Scott JA & Crews FT (1986). Down-regulation of serotonin2, but not of beta-adrenergic receptors during chronic treatment with amitriptyline is independent of stimulation of serotonin2 and beta-adrenergic receptors. Neuropharmacology 25, 1301-1306.
56. Sekiguchi M, Zushida K, Yoshida M, Maekawa M, Kamichi S, Sahara Y, Yuasa S, Takeda S & Wada K (2009). A deficit of brain dystrophin impairs specific amygdala GABAergic transmission and enhances defensive behaviour in mice. Brain 132, 124-135.
57. Smith RS (1991). The macrophage theory of depression. Med Hypotheses 35, 298-306.
58. Snyder JS, Soumier A, Brewer M, Pickel J & Cameron HA (2011). Adult hippocampal neurogenesis buffers stress responses and depressive behaviour. Nature 476, 458-461.
59. Song C, Merali Z & Anisman H (1999). Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment. Neuroscience 88, 823-836.
60. Spurney CF, Gordish-Dressman H, Guerron AD, Sali A, Pandey GS, Rawat R, Van Der Meulen JH, Cha HJ, Pistilli EE, Partridge TA, Hoffman EP & Nagaraju K (2009). Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve 39, 591-602.
61. Stahl SM (1998). Basic psychopharmacology of antidepressants, part 1: antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 59 Suppl 4, 5-14.
62. Steru L, Chermat R, Thierry B & Simon P (1985). The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 85, 367-370.
63. Taghian F, Esteki Ghashghaei F, Badami R & Esteki Ghashghaei S (2011). Comparison the effect of one session submaximal exercise on plasma levels of IL6 and TNF- a in obese and non-obese women. ARYA Atheroscler 6, 153-156.
64. Tai YH, Wang YH, Wang JJ, Tao PL, Tung CS & Wong CS (2006). Amitriptyline suppresses neuroinflammation and up-regulates glutamate transporters in morphine-tolerant rats. Pain 124, 77-86.
65. Takeuchi T, Owa T, Nishino T & Kamei C (2010). Assessing anxiolytic-like effects of selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors using the elevated plus maze in mice. Methods Find Exp Clin Pharmacol 32, 113-121.
66. Tatsumi M, Groshan K, Blakely RD & Richelson E (1997). Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340, 249-258.
67. Tousoulis D, Drolias A, Antoniades C, Vasiliadou C, Marinou K, Latsios G, Stefanadi E, Gounari P, Siasos G, Papageorgiou N, Trikas A & Stefanadis C (2009). Antidepressive treatment as a modulator of inflammatory process in patients with heart failure: effects on proinflammatory cytokines and acute phase protein levels. Int J Cardiol 134, 238-243.
68. Troelsen KB, Nielsen EO & Mirza NR (2005). Chronic treatment with duloxetine is necessary for an anxiolytic-like response in the mouse zero maze: the role of the serotonin transporter. Psychopharmacology (Berl) 181, 741-750.
69. Vaillend C, Rendon A, Misslin R & Ungerer A (1995). Influence of dystrophin-gene mutation on mdx mouse behaviour. I. Retention deficits at long delays in spontaneous alternation and bar-pressing tasks. Behav Genet 25, 569-579.
70. van West D & Maes M (1999). Activation of the inflammatory response system: a new look at the etiopathogenesis of major depression. Neuro Endocrinol Lett 20, 11-17.
71. Walsh RN & Cummins RA (1976). The Open-Field Test: a critical review. Psychol Bull 83, 482-504.
72. Wang J & Dunn AJ (1998). Mouse interleukin-6 stimulates the HPA axis and increases brain tryptophan and serotonin metabolism. Neurochem Int 33, 143-154.
73. Weiss SM, Lightowler S, Stanhope KJ, Kennett GA & Dourish CT (2000). Measurement of anxiety in transgenic mice. Rev Neurosci 11, 59-74.
74. Xia Z, DePierre JW & Nassberger L (1996). Tricyclic antidepressants inhibit IL-6, IL-1β and TNF-α release in human blood monocytes and IL-2 and interferon-γ in T cells. Immunopharmacology 34, 27-37.
75. Yiu EM & Kornberg AJ (2008). Duchenne muscular dystrophy. Neurol India 56, 236-247.
76. Zalcman S, Green-Johnson JM, Murray L, Nance DM, Dyck D, Anisman H & Greenberg AH (1994). Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res 643, 40-49.
77. Zielinski TA, Brown ES, Nejtek VA, Khan DA, Moore JJ & Rush AJ (2000). Depression in asthma: Prevalence and clinical implications. Prim Care Companion J Clin Psychiatry 2, 153-158.
78. Zunszain PA, Hepgul N & Pariante CM (2013). Inflammation and depression. Curr Top Behav Neurosci 14, 135-151.